<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04776252</url>
  </required_header>
  <id_info>
    <org_study_id>8591A-033</org_study_id>
    <secondary_id>MK-8591A-033</secondary_id>
    <secondary_id>2020-001191-14</secondary_id>
    <nct_id>NCT04776252</nct_id>
  </id_info>
  <brief_title>Open-label, Follow-up of Doravirine/Islatravir for Participants With Human Immunodeficiency Virus -1 (HIV-1) Infection (MK-8591A-033)</brief_title>
  <official_title>A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The safety and tolerability of MK-8591A, a novel 2-drug fixed dose combination (FDC) of&#xD;
      doravirine (DOR) and islatravir (ISL) will be evaluated in adult and pediatric participants&#xD;
      with Human Immunodeficiency Virus -1 (HIV-1) who were treated with DOR and ISL in earlier&#xD;
      clinical studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2021</start_date>
  <completion_date type="Anticipated">February 16, 2029</completion_date>
  <primary_completion_date type="Anticipated">May 15, 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants with serious adverse events (SAEs)</measure>
    <time_frame>Up to Week 54</time_frame>
    <description>Percentage of participants with serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants who discontinued due to an adverse event (AE)</measure>
    <time_frame>Up to Week 48</time_frame>
    <description>Percentage of participants who discontinued study treatment due to an AE.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>MK-8591A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination (FDC) tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-8591A</intervention_name>
    <description>FDC tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for 48 weeks</description>
    <arm_group_label>MK-8591A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Is currently receiving DOR/ISL adult FDC tablet in a Merck-sponsored clinical study&#xD;
             and has completed the last treatment visit.&#xD;
&#xD;
          -  Is considered by the investigator to have derived clinical benefit from receiving&#xD;
             DOR/ISL and for whom further treatment with DOR/ISL is considered clinically&#xD;
             appropriate.&#xD;
&#xD;
          -  Is male or female and ≥35 kg at the time of signing the informed consent/assent.&#xD;
&#xD;
          -  Female is not pregnant or breastfeeding, and at least one of the following conditions&#xD;
             applies: Is not a woman of childbearing potential (WOCBP); or is a non-pregnant WOCBP&#xD;
             who agrees to the following during the intervention period and for at least 6 weeks&#xD;
             after the last dose of study intervention: Not be sexually active, or if sexually&#xD;
             active, to use an acceptable method of contraception; or is pregnant and continues to&#xD;
             receive study intervention (where allowed by local regulations and as appropriate&#xD;
             based on available data/local standard-of-care guidelines).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Is taking or is anticipated to require any prohibited therapies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pueblo Family Physicians ( Site 0010)</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>602-264-9191</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Whitman-Walker Institute ( Site 0039)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>202-745-7000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center ( Site 0017)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>407-647-3960</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northstar Healthcare ( Site 0003)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>773-296-2400</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>KC CARE Health Center-Clinical Trials ( Site 0012)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>816-777-2759</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Hope Foundation ( Site 0041)</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-839-7111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Texas Infectious Diseases Consultants, P.A-Research ( Site 0004)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>214-823-2533</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Crofoot Research Center ( Site 0008)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>713-526-0005</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital hernan henriquez aravena de temuco-Unidad de Investigación Clínica ( Site 0202)</name>
      <address>
        <city>Temuco</city>
        <state>Araucania</state>
        <zip>4781151</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>56452556805</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Biomedica Research Group-Infectology ( Site 0201)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>7500710</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>5622204568</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Arauco Salud ( Site 0200)</name>
      <address>
        <city>Santiago</city>
        <state>Region M. De Santiago</state>
        <zip>7560590</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>56992280653</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Avicenne ( Site 1502)</name>
      <address>
        <city>Bobigny</city>
        <state>Ile-de-France</state>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>0148955421</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-Dieu ( Site 1517)</name>
      <address>
        <city>Nantes</city>
        <state>Loire-Atlantique</state>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33240083372</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital ( Site 2102)</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>NW32QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+442074726232</phone>
    </contact>
  </location>
  <location_countries>
    <country>Chile</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 26, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Islatravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

